Dr. Russell Dahl is the CEO and founder of Neurodon.

Russell is the CEO and scientific founder of Neurodon. Previously, he led all small molecule research at Celladon, where he was responsible for progressing a diverse small molecule pipeline into the clinic. He started his career in industry at Agouron Pharmaceuticals, progressing through positions of increasing responsibility at DuPont Pharmaceuticals, BMS, Vertex, and Kemia. During his tenure in the industry, he contributed to 13 molecules reaching advanced tox studies with 6 entering clinical trials.

Russell has also been involved in many successful biotech startups as a founder or advisor, having been directly involved in raising over $500M in funding including non-dilutive capital and 2 successful IPOs. His experience spans all phases of development and he has contributed to several IND filings and regulatory approvals. Russell has co-authored over 80 scientific publications and is an inventor on over 50 patent applications.

He is a former Professor of Neuroscience and Medicinal Chemistry and received his Ph.D. in organic chemistry from the University of California, San Diego as a DuPont pharmaceuticals fellow and has additional training in molecular pharmacology from Stanford University.